Drug intelligence / Profile preview

RO7617991

Development stage: Discontinued
Lead developer: Genentech
Modality: T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
Administration: Intravenous

Overview

RO7617991 is an investigational anticancer drug developed by Genentech for the treatment of solid tumors that express melanoma-associated antigen A4 (MAGE-A4) and are positive for the HLA-A*02 haplotype. It is a CD3-directed T-cell engager designed to target MAGE-A4-positive cancer cells, facilitating immune-mediated tumor cell killing. The drug was intended for intravenous administration in patients with locally advanced or metastatic MAGE-A4-positive solid tumors. Development was discontinued before any patients were enrolled in clinical trials, following a strategic review unrelated to safety or efficacy concerns[1][2][3][5].

Targets

CD3 (T-cell surface glycoprotein CD3)MAGE-A4 peptide-HLA-A*02:01 complex

Beyond the preview

Go deeper on RO7617991.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RO7617991.

Explore the full profile